AMGN Jun 2023 245.000 call

OPR - OPR Prezzo differito. Valuta in USD.
0,1000
0,0000 (0,00%)
Al 03:11PM EDT. Mercato aperto.
Il grafico dei titoli non è supportato dal tuo browser attuale
Chiusura precedente0,1000
Aperto0,1200
Denaro0,0500
Lettera0,1200
Prezzo d'esercizio245,00
Scadenza2023-06-16
Min-Max giorno0,0600 - 0,1200
Contratto - Min-MaxN/D
Volume51
Open Interest1,35k
  • GlobeNewswire

    Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn’s Disease

    Collaboration Brings Together TScan’s Proprietary Target Discovery Platform and Amgen’s Inflammation Therapeutic Expertise and Research Capabilities TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million THOUSAND OAKS, Calif. and WALTHAM, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and TScan Therapeutics, Inc. (NASDAQ:TCRX), today announced a multi-year collaboration that will use TScan’s proprietary target discovery